Alexander Schramm researcher
Schramm, Alexander
VIAF ID: 7090158792793339040003 (Personal)
Permalink: http://viaf.org/viaf/7090158792793339040003
Preferred Forms
- 100 0 _ ‡a Alexander Schramm ‡c researcher
- 100 1 _ ‡a Schramm, Alexander
4xx's: Alternate Name Forms (3)
5xx's: Related Names (5)
- 551 _ _ ‡a Essen ‡4 ortg ‡4 https://d-nb.info/standards/elementset/gnd#placeOfBirth
- 510 2 _ ‡a Innere Klinik und Poliklinik (Tumorforschung) ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Ruhr-Universität Bochum ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Universität Duisburg-Essen ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
- 510 2 _ ‡a Zentrum für Medizinische Biotechnologie ‡g Essen ‡4 affi ‡4 https://d-nb.info/standards/elementset/gnd#affiliation ‡e Affiliation
Works
Title | Sources |
---|---|
IL-2−driven Regulation of NK Cell Receptors With Regard to the Distribution of CD16+ and CD16− Subpopulations and In Vivo Influence After Haploidentical NK Cell Infusion | |
Advances and innovations in computer-assisted head and neck oncologic surgery. | |
Amplification of N-Myc is associated with a T-cell-poor microenvironment in metastatic neuroblastoma restraining interferon pathway activity and chemokine expression | |
ArrayCGH-based classification of neuroblastoma into genomic subgroups | |
The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia. | |
Bedeutung der Lysin-spezifischen Histon-Demethylase 1 (LSD1/KDM1A) im Medulloblastom und in seinen Vorläuferzellen | |
CADM1 is a strong neuroblastoma candidate gene that maps within a 3.72 Mb critical region of loss on 11q23 | |
Chromosomal and microRNA expression patterns reveal biologically distinct subgroups of 11q- neuroblastoma | |
Deep sequencing reveals differential expression of microRNAs in favorable versus unfavorable neuroblastoma | |
Design of a modular protein-based MRI contrast agent for targeted application. | |
Design of a multi-signature ensemble classifier predicting neuroblastoma patients' outcome | |
Discovery of a new bioactive molecule for neuroblastoma | |
Fractalkine (CX3CL1)- and interleukin-2-enriched neuroblastoma microenvironment induces eradication of metastases mediated by T cells and natural killer cells. | |
Frequent codeletion of p16/MTS1 and p15/MTS2 and genetic alterations in p16/MTS1 in pancreatic tumors. | |
Functional screening identifies aryl hydrocarbon receptor as suppressor of lung cancer metastasis | |
Gains and overexpression identify DEK and E2F3 as targets of chromosome 6p gains in retinoblastoma. | |
Galectin-1 is a major effector of TrkB-mediated neuroblastoma aggressiveness. | |
High ALK receptor tyrosine kinase expression supersedes ALK mutation as a determining factor of an unfavorable phenotype in primary neuroblastoma | |
High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors | |
Homozygous loss of the MTS1/p16 and MTS2/p15 genes in lymphoma and lymphoblastic leukaemia cell lines | |
Human fetal neuroblast and neuroblastoma transcriptome analysis confirms neuroblast origin and highlights neuroblastoma candidate genes | |
Identification and Tumour-Binding Properties of a Peptide with High Affinity to the Disialoganglioside GD2. | |
Identification of a novel recurrent 1q42.2-1qter deletion in high risk MYCN single copy 11q deleted neuroblastomas | |
Identification of dynamic proteome changes upon ligand activation of Trk-receptors using two-dimensional fluorescence difference gel electrophoresis and mass spectrometry. | |
Immunomodulation by immune checkpoint inhibitors in preclinic models of retinoblastoma | |
Lysine-specific demethylase 1 is strongly expressed in poorly differentiated neuroblastoma: implications for therapy | |
Lysine-specific demethylase 1 restricts hematopoietic progenitor proliferation and is essential for terminal differentiation | |
A mechanistic classification of clinical phenotypes in neuroblastoma | |
Meta-mining of neuroblastoma and neuroblast gene expression profiles reveals candidate therapeutic compounds | |
The metallophosphodiesterase Mpped2 impairs tumorigenesis in neuroblastoma. | |
MiR-137 functions as a tumor suppressor in neuroblastoma by downregulating KDM1A. | |
The miR-17-92 microRNA cluster regulates multiple components of the TGF-β pathway in neuroblastoma | |
MiR-34a deficiency accelerates medulloblastoma formation in vivo | |
Modulation of neuroblastoma disease pathogenesis by an extensive network of epigenetically regulated microRNAs | |
Modulation of the cellular irradiation response through neurotrophin receptors TrkA/NTRK1 and TrkB/NTRK2 in neuroblastoma | |
Mutational dynamics between primary and relapse neuroblastomas. | |
MYCN and ALKF1174L are sufficient to drive neuroblastoma development from neural crest progenitor cells | |
MYCN/c-MYC-induced microRNAs repress coding gene networks associated with poor outcome in MYCN/c-MYC-activated tumors. | |
N-Myc-induced metabolic rewiring creates novel therapeutic vulnerabilities in neuroblastoma | |
Neuroblastoma tumorigenesis is regulated through the Nm23-H1/h-Prune C-terminal interaction | |
Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas | |
Polo-like kinase 1 is a therapeutic target in high-risk neuroblastoma | |
A prospective multicenter study to compare the precision of posttraumatic internal orbital reconstruction with standard preformed and individualized orbital implants | |
A quantitative approach to orbital decompression in Graves' disease using computer-assisted surgery: a compilation of different techniques and introduction of the "temporal cage". | |
Reanalysis of neuroblastoma expression profiling data using improved methodology and extended follow-up increases validity of outcome prediction | |
Smac mimetic LBW242 sensitizes XIAP-overexpressing neuroblastoma cells for TNF-α-independent apoptosis | |
Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: Insights from 2-year DUTCH PEERS (TWENTE II) randomized trial | |
Streamlining Quantitative Analysis of Long RNA Sequencing Reads | |
Synthetic lethality between Rb, p53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation | |
Taraxacum officinale extract shows antitumor effects on pediatric cancer cells and enhance mistletoe therapy | |
Targeted expression of mutated ALK induces neuroblastoma in transgenic mice. | |
Targeting the phosphoinositide 3-kinase isoform p110delta impairs growth and survival in neuroblastoma cells. | |
TCT-19 Two-Year Clinical Outcome and Chest Pain in 1,811 All-Comer Patients, Treated for Bifurcated Versus Non-Bifurcated Lesions With Highly Deliverable Drug-Eluting Coronary Stents | |
TCT-570 3-Year Clinical Outcome of the DUTCH PEERS (TWENTE II) Randomized Trial: Cobalt-Chromium Zotarolimus-Eluting Resolute Integrity Versus Platinum-Chromium Everolimus-Eluting Promus Element Stents in All-Comer Patients | |
Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial | |
Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. | |
TrkB-Target Galectin-1 Impairs Immune Activation and Radiation Responses in Neuroblastoma: Implications for Tumour Therapy. | |
Xenogeneic immunization with human tyrosine hydroxylase DNA vaccines suppresses growth of established neuroblastoma. |